Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oxford GlycoSciences Plc -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (273)	12/27/2002 11:37:56 AM
From: scaram(o)uche	Respond to of 469

H&Q, Bear Stearns and SG Cowen were trying to get them out the door one year ago...... sec.gov Under our current collaborations, we expect to screen approximately 240 different proteins. The table below summarizes our current collaborations: -------------------------------------------------------------------------------- Collaborator Effective date of agreement Initial term -------------------------------------------------------------------------------- Aventis December 31, 2001 3 years Immusol October 18, 2001 3 years Tularik August 30, 2001 less than 1 year Schering-Plough August 2, 2001 2 years Celltech July 11, 2001 4.5 years Mitsubishi Pharma July 4, 2001 1 year Biogen June 29, 2001 39 months Oxford GlycoSciences June 18, 2001 3 years -------------------------------------------------------------------------------- We know that the Mitsubishi collaboration has gone well.

To: scaram(o)uche who wrote (273)	12/27/2002 11:55:08 AM
From: nigel bates	Read Replies (2) \| Respond to of 469

Reformat <g> 5. Other investments BioInvent NeoGenesis International Pharmaceuticals AB Inc Total '000 pounds '000 pounds '000 pounds Cost: At 1 January 2002 -- 4,251 4,251 Additions 3,528 - 3,528 At 30 June 2002 3,528 4,251 7,779 Provisions: At 1 January 2002 and 30 June 2002 -- -- -- Net book value: At 30 June 2002 3,528 4,251 7,779 Net book value: At 31 December 2001 -- 4,251 4,251 They announced the deal in June 2001 (& didn't give financial details at the time) Message 15968582 I'll see if I can find the % stake, but presumably it's less than 10% ? (edit) Parking some other equity investments : CAMBRIDGE, Mass., January 08, 2001 - NeoGenesis Inc., an applied genomics and drug discovery technology company based here, today announced that it has completed a $23 million Series D financing. OrbiMed Advisors LLC of New York is the lead investor in a group, including Ft. Washington Private Equity Investors, Essex Street Associates and Valentine Partners. Michael B. Sheffery, Ph.D., a managing general partner at OrbiMed will join the NeoGenesis Board of Directors... July 2001 Under the terms of the agreement, Celltech will provide disease targets against which NeoGenesis will apply its screening technology to identify new drug discovery leads. Celltech will provide research funding for NeoGenesis, in addition to payments upon achieving certain milestones. Celltech will be responsible for the commercialization of all products arising from the collaboration and will make royalty payments to NeoGenesis on sales of such products. Celltech will also make a $10 million equity investment in NeoGenesis as part of the agreement. Aug 6 2001 Under terms of the agreement, Schering-Plough will make an equity investment in NeoGenesis and will provide research and development funding, which may extend over a period of up to five years. NeoGenesis expects to receive license fees as well as payments upon the achievement of certain defined clinical and regulatory milestones. In addition, NeoGenesis will receive royalties on any commercial sales of products resulting from the collaboration.